

LRRC72 (N-17): sc-247487

BACKGROUND

LOC100129335 is a 287 amino acid leucine-rich repeat-containing protein containing four LRR (leucine-rich) repeats and one LRRCT domain. The gene encoding LOC100129335 maps to human chromosome 7, which houses over 1,000 genes and comprises nearly 5% of the human genome. Chromosome 7 has been linked to Osteogenesis imperfecta, Pendred syndrome, Lissencephaly, Citrullinemia and Shwachman-Diamond syndrome. The deletion of a portion of the q arm of chromosome 7 is associated with Williams-Beuren syndrome, a condition characterized by mild mental retardation, an unusual comfourt and friendliness with strangers and an elfin appearance. Deletions of portions of the q arm of chromosome 7 are also seen in a number of myeloid disorders including cases of acute myelogenous leukemia and myelodysplasia.

REFERENCES

1. Tspirouras, P., et al. 1983. Restriction fragment length polymorphism associated with the pro α 2(I) gene of human type I procollagen. Application to a family with an autosomal dominant form of osteogenesis imperfecta. *J. Clin. Invest.* 72: 1262-1267.
2. Liang, H., et al. 1998. Molecular anatomy of chromosome 7q deletions in myeloid neoplasms: evidence for multiple critical loci. *Proc. Natl. Acad. Sci. USA* 95: 3781-3785.
3. Ko, M.S., et al. 2000. Large-scale cDNA analysis reveals phased gene expression patterns during preimplantation mouse development. *Development* 127: 1737-1749.
4. Eckert, M.A., et al. 2006. The neurobiology of Williams syndrome: cascading influences of visual system impairment? *Cell. Mol. Life Sci.* 63: 1867-1875.
5. Osborne, L.R., et al. 2006. Williams-Beuren syndrome diagnosis using fluorescence *in situ* hybridization. *Methods Mol. Med.* 126: 113-128.
6. Reiner, O., et al. 2006. Lissencephaly 1 linking to multiple diseases: mental retardation, neurodegeneration, schizophrenia, male sterility, and more. *Neuromolecular Med.* 8: 547-565.
7. Gilbert-Dussardier, B. 2006. Williams-Beuren syndrome. *Rev. Prat.* 56: 2102-2106.
8. Leone, G., et al. 2007. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. *Haematologica* 92: 1389-1398.

CHROMOSOMAL LOCATION

Genetic locus: LRRC72 (human) mapping to 7p21.1.

SOURCE

LRRC72 (N-17) is an affinity purified goat polyclonal antibody raised against a peptide mapping at the N-terminus of LRRC72 of human origin.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

PRODUCT

Each vial contains 200 μ g IgG in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

Blocking peptide available for competition studies, sc-247487 P, (100 μ g peptide in 0.5 ml PBS containing < 0.1% sodium azide and 0.2% BSA).

APPLICATIONS

LRRC72 (N-17) is recommended for detection of LRRC72 of human origin by Western Blotting (starting dilution 1:200, dilution range 1:100-1:1000), immunofluorescence (starting dilution 1:50, dilution range 1:50-1:500) and solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

Molecular Weight of LRRC72: 44 kDa.

RECOMMENDED SECONDARY REAGENTS

To ensure optimal results, the following support (secondary) reagents are recommended: 1) Western Blotting: use donkey anti-goat IgG-HRP: sc-2020 (dilution range: 1:2000-1:100,000) or Cruz Marker™ compatible donkey anti-goat IgG-HRP: sc-2033 (dilution range: 1:2000-1:5000), Cruz Marker™ Molecular Weight Standards: sc-2035, TBS Blotto A Blocking Reagent: sc-2333 and Western Blotting Luminol Reagent: sc-2048. 2) Immunofluorescence: use donkey anti-goat IgG-FITC: sc-2024 (dilution range: 1:100-1:400) or donkey anti-goat IgG-TR: sc-2783 (dilution range: 1:100-1:400) with UltraCruz™ Mounting Medium: sc-24941.

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.